Rheumatoid arthritis

Med Clin (Barc). 2023 Dec 22;161(12):533-542. doi: 10.1016/j.medcli.2023.07.014. Epub 2023 Aug 9.
[Article in English, Spanish]

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory multisystemic disease of unknown etiology and autoimmune nature that predominantly affects peripheral joints in a symmetrical fashion. Although much progress has been made in understanding the pathophysiology of RA, its etiology remains unknown. Tumor necrosis factor (TNF)-α and interleukin (IL)-6 play the important roles in the pathogenesis and maintenance of inflammation in RA. The presence of anti-citrullinated peptide antibodies aids in the diagnosis in patients with undifferentiated polyarthritis and is associated with a more aggressive RA. The natural history of RA causes joint deformity and disability, as well as reduced life expectancy, both due to increased cardiovascular risk, pulmonary involvement, infections, iatrogenesis or tumors. Early diagnosis and the use of targeted drugs to induce early remission have improved the RA prognosis.

Keywords: Actividad de la enfermedad; Artritis reumatoide; Disease activity; Estrategia treat to target; Etiopathogenesis; Etiopatogenia; Rheumatoid arthritis; Tratamiento; Treat to target strategy; Treatment.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arthritis, Rheumatoid* / complications
  • Arthritis, Rheumatoid* / diagnosis
  • Humans
  • Interleukin-6
  • Prognosis
  • Tumor Necrosis Factor-alpha

Substances

  • Interleukin-6
  • Tumor Necrosis Factor-alpha